NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Gilead Sciences, Inc. (GILD) Stock Analysis

Gilead Sciences, Inc. (GILD) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

GILD

$151.00

−$0.22 (−0.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GILD with… →

GILD Key Statistics

As of Sep 4, 2026
Trading
Open
$149.23
Previous Close
$151.22
Day's Range
149.23–151.19
52-Week Range
108.46–157.29
Volume
6.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.35
Valuation
Market Cap
$187.23B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.27
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.03
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.64
Financials (FY)
Revenue (FY)
$29.44B+2.39%
Net Income (FY)
$8.51B+1672.92%
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.24B
1-Year Return
+37.39%
Dividend and dates
Dividend
$3.28+2.17%
Ex-Dividend Date
September 15, 2026
Earnings Date
October 29, 2026
Avg Volume
7.10M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GILD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.54%
2025+36.59%
2024+18.68%
2023−1.99%
2022+23.63%
2021+29.96%
2020−6.70%
2019+7.88%
2018−9.92%
2017+2.96%
2016 (partial year)−9.07%

As of September 4, 2026.

GILD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$29.44B$8.51B28.9%
2024$28.75B$480.00M1.7%
2023$27.12B$5.67B20.9%
2022$27.28B$4.59B16.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$29.44B$23.21B$11.70B$8.51B28.9%
2024$28.75B$22.50B$10.60B$480.00M1.7%
2023$27.12B$20.62B$8.84B$5.67B20.9%
2022$27.28B$21.62B$10.97B$4.59B16.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GILD Dividend History

$3.16+2.6% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$1.642—
2025$3.164+2.6%
2024$3.084+2.7%
2023$3.004+2.7%
YearDividends per sharePaymentsChange
2026 (partial year)$1.642—
2025$3.164+2.6%
2024$3.084+2.7%
2023$3.004+2.7%
2022$2.924+2.8%
2021$2.844+4.4%
2020$2.724+7.9%
2019$2.524+10.5%
2018$2.284+9.6%
2017$2.084+121.3%
2016$0.942—

Most recent payment: $0.82 per share, ex-dividend June 15, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

GILD Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricGILDDrug Manufacturers - General medianvs median
P/S ratio6.153.1396% above
Profit margin−10.64%8.09%18.7 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Gilead Sciences, Inc. (GILD) at $187.23B. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. The company reports 17,000 employees.

The 52-week range on file runs from $108.46 to $157.29. GILD last closed at $151.00 on September 4, 2026. That is −$0.22 (−0.15%) against the previous close. The latest close sits 39.22% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $29.44B. Against the prior fiscal year total of $28.75B, that is a change of +2.39%. Net income for the same year was $8.51B. That is +1,672.92% against the prior fiscal year. Profit margin runs at −10.64%. That is 18.7 percentage points below the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are −2.64.

Across the 4 fiscal years on file, revenue moves from $27.28B in 2022 to $29.44B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 15.27. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.03. Measured against sales, the shares trade at 6.15 times revenue. On price-to-sales that is 96.3% above the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Over the trailing twelve months the price has returned +37.39%. Measured over 10 years, that is +10.84% a year compounded. The reported beta is 0.35. Daily returns over the trailing 10 years annualize to a volatility of 25.56%.

Growth & Income

Shareholders receive a dividend, yielding 2.17% on the latest price. That is 0.5 percentage points below the Drug Manufacturers - General median yield of 2.7%. The indicated annual rate is $3.28 a share. The ex-dividend date on file is September 15, 2026. Dividends are recorded for 11 calendar years; 2026 shows 2 payments totalling $1.64 a share. The year before, 2025, totalled $3.16 a share.

So far in 2026 the price is +24.54%. Across the complete calendar years on file, 2025 returned +36.59% and 2018 returned −9.92%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Gilead Sciences, Inc. (GILD) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Gilead Sciences, Inc. GILD $187.23B —
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Gilead Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Visit website →